Stocks · Healthcare · Biotechnology
Cullinan Therapeutics, Inc. CGEM
$15.51 +6.74% Close, Oct 2, 2026 · NASDAQ · Market cap $953.2M
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Over the past year the stock returned +158.5%, ahead of the S&P 500 by 143.4 percentage points.
- The company holds net cash of $76.6M (cash above total debt).
- The stock is 32% below its highest close of the past year.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 17%
- Accruals (lower is better)Top 28%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 31%
- Free-cash-flow yieldBottom 28%
- EBITDA / enterprise valueBottom 25%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 4%
- 6-month returnTop 49%
- 1-year return vs S&P 500Top 7%
- Distance from 52-week highBottom 48%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersTop 42%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetTop 31%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 22%
- Maximum drawdown, 3 yearsBottom 32%
- Beta vs S&P 500 (lower is better)Top 34%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Return on invested capital | -68.5% | — | Bottom 17% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -12.5%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -0.23%
- Shareholder yield
- -0.23%
- Share count change, 1 year
- +4.2%
- Share count change, 3-year CAGR
- +15.5%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- +7.9%
- Average 2-day reaction, last 8
- -1.9%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $34.75
- Target vs current price
- +124.0%
- Analysts with a rating
- 8
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | -1.3% | +1.9% | +11.3% | +26.8% | — |
| May 7, 2026 | +10.3% | -1.8% | +8.9% | -3.7% | +8.4% |
| Mar 10, 2026 | +3.8% | -2.6% | -8.4% | -2.9% | -0.7% |
| Nov 6, 2025 | +18.9% | +0.5% | +14.2% | +44.7% | +80.7% |
| Aug 7, 2025 | -28.9% | -10.8% | -3.0% | -12.3% | -4.1% |
| May 8, 2025 | +5.1% | +0.9% | -7.4% | +13.5% | +3.1% |
| Feb 27, 2025 | +2.7% | +1.9% | -0.2% | -4.3% | -6.6% |
| Nov 7, 2024 | +11.5% | -5.5% | -4.2% | -24.5% | -37.5% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.81 | -$0.80 | -1.3% | — |
| May 7, 2026 | -$0.75 | -$0.84 | +10.3% | — |
| Mar 10, 2026 | -$0.77 | -$0.80 | +3.8% | — |
| Nov 6, 2025 | -$0.77 | -$0.95 | +18.9% | — |
| Aug 7, 2025 | -$1.07 | -$0.83 | -28.9% | — |
| May 8, 2025 | -$0.74 | -$0.78 | +5.1% | — |
| Feb 27, 2025 | -$0.73 | -$0.75 | +2.7% | — |
| Nov 7, 2024 | -$0.69 | -$0.78 | +11.5% | — |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| Free-cash-flow yield | -16.71% | — | — | Bottom 28% |
| Earnings yield | -21.73% | — | — | Bottom 31% |
P/E over the past five years
Range 4.7× – 7.9× since Jun 30, 2022. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 1
- 50-day average slope (20 days)
- +2.0%
- 200-day average slope (20 days)
- +5.5%
- Distance from 50-day average
- -20.2%
- Distance from 200-day average
- +1.0%
- RSI (14)
- 33.3
- Relative volume
- 0.91×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 74.8%
- Volatility vs own 5-year history
- 83th percentile · High for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.86
- Correlation with S&P 500
- 0.19
- Current drawdown from 1-year high
- -32.4%
- Maximum drawdown, 3 years
- -80.4%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 10, 2021 | Oct 2, 2025 | -89.2% | 1147 days | Not yet recovered |
| Mar 2, 2021 | Mar 4, 2021 | -17.3% | 2 days | 4 days (Mar 10, 2021) |
| Jan 25, 2021 | Feb 3, 2021 | -12.6% | 7 days | 6 days (Feb 11, 2021) |
| Feb 19, 2021 | Feb 26, 2021 | -11.6% | 5 days | 1 days (Mar 1, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $953.2M
- EPS, diluted (TTM)
- -$3.37
- Revenue (TTM)
- $0
- 52-week range
- $5.68 – $23.19
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $18.9M | $0 | $0 | $0 | $0 |
| Gross profit | $18.9M | $0 | $0 | -$306,000 | $0 |
| Operating income | -$68.0M | $144.6M | -$191.1M | -$196.9M | -$241.6M |
| Net income | -$65.6M | $111.2M | -$153.2M | -$167.4M | -$219.9M |
| EPS (diluted) | -$1.48 | $2.38 | -$3.69 | -$3.11 | -$3.72 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$40.6M | -$47.6M | -$48.5M | -$70.1M | -$50.6M | -$50.7M | -$49.7M | -$53.7M |
| EPS (diluted) | -$0.70 | -$0.81 | -$0.82 | -$1.19 | -$0.86 | -$0.86 | -$0.84 | -$0.81 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$43.4M | -$126.7M | -$134.3M | -$145.3M | -$175.8M |
| Capital expenditure | -$589,225 | -$1.1M | -$208,000 | $0 | -$49,000 |
| Free cash flow | -$44.0M | -$127.8M | -$134.5M | -$145.3M | -$175.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $267.3M | $8.4M | $38.4M | $262.7M | $1.1M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $334.5M
- Total assets
- $363.8M
- Total liabilities
- $42.0M
- Total debt
- $2.1M
- Net debt
- -$76.6M
- Shareholders’ equity
- $321.8M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 9,629,017
- Days to cover
- 10.88
- Change vs previous report
- -7.2%
FINRA short interest, settlement date Sep 15, 2026.